Division of Rheumatology

Walter F. Kean

MB ChB, MD(Glas) FRCP (Glas, Edin & C)

Service of Rheumatology, Hamilton Health Sciences

Clinical Professor in Medicine, McMaster University

 

 

Education and Professional Standing

Walter F Kean is a Clinical Professor in Medicine (Rheumatology). He graduated in Medicine, MB ChB from Glasgow University in 1972, and gained a research Doctorate degree in Medicinal Science from Glasgow University in 1983 (MD Glas) for a thesis on laboratory studies of gold thiol structural chemistry and the interaction of gold thiol compounds and therapeutic agents with platelets, and complementary clinical studies on the effects of gold thiol compounds on patients with rheumatoid arthritis. The supervisors were: Professors Colin Lock, Chemistry; Fraser Mustard, Molecular Biology; and W Watson Buchanan, Clinical Medicine (Rheumatology).

Walter F Kean became a Fellow of the Royal College of Physicians (FRCP) Canada in 1978. He was a founding Fellow of the American College of Rheumatology (FACR) 1986. He is a Fellow of the Royal College of Physicians and Surgeons of Glasgow, and a Fellow of the Royal College of Physicians of Edinburgh. He was head of clinical service in Rheumatology 1991-2007 at Hamilton Health Sciences. A CV is available on request from keanmac@cogec.ca or 905-521-0514. The information listed below is a brief summary of recent academic activities.

Clinical Activities

Osteoarthritis: hand pain; shoulder pain; knee pain; spinal pain. EMG diagnosis of musculoskeletal pain; joint injections and nerve block injections for treatment of refractory musculoskeletal pain.

Educational Activities

He is a regular participant in rheumatology post graduate and under graduate clinical teaching on a daily basis. He has supervised elective under graduate and post graduate students in Family Medicine and Internal Medicine: and has supervised elective under graduate and post graduate students from across Canada and international universities.

Each year he is a supervisor to one or more undergraduate investigators for the McMaster University BSc Health Science thesis project.

Details of educational activity can be obtained from:

  1. Mrs. Rennee Tremblay, Administrator, Division of Rheumatology Education.
  2. Mrs. Jane Bennett, McMaster University Undergraduate M.D. program.
  3. Office of Postgraduate Education, McMaster University.

Recognition

Invited Delphi panel member for the World Health Organisation (WHO), in establishing international Core Set Values for rheumatoid arthritis - 2006.

Invited to contribute article on Clinical Pharmacology of Gold complexes for Dr. M. Whitehouse. Special Journal Issue: Re-Appraisal of Gold in Rheumatic Diseases. Kean WF, Kean IR. Clinical pharmacology of gold. Inflammopharmacology. 2008 Jun;16(3):112-25. Review. W.F. Kean invited author.

Invited Chairman – several sessions. 9th International Conference on Inflammopharmacology, Side Effects of Anti- Inflammatory Drugs. Queen’s College Cambridge UK, Sept 8-10, 2008.

Invited to speak on “Gold Complexes”. 9th International Conference on Inflammopharmacology, Side Effects of Anti- Inflammatory Drugs. Queen’s College Cambridge UK, Sept 8-10, 2008.

Invited speak on: The Musculoskeletal Problems of the Similuan Iceman.

The Annual John McRae lecture January 15, 2011, McMaster University.

The Hamilton Association of Literature, Arts and Science (HALSA) established 1857.

Awarded: Certificate of Merit for Teaching Excellence, 2008 – 2010. McMaster University Department of Medicine, Internal Medicine Residency Program.

Invited panellist. Inflammopharmacology Meeting, Department of Pharmacology, Queens’ College Cambridge, UK, July 5, 2011.

Additional Interests

Editorial board member of the journal, Current Medical Research and Opinion since 2004 -2010. Assistant Editor, Clinical Studies, and editorial board member of the journal, Inflammopharmacology.  He has been a member of the Inflammopharmacology Journal Editorial advisory board since 1995, and was promoted to Editorial Consultant, Inflammopharmacology Journal in 2003. He was promoted to Assistant Editor Clinical Studies in 2006.  He advises on journal content, symposia content, and edits articles for review.

Research

The current main search interests have been in anti-rheumatic drug pharmacology and clinical actions, and osteoarthritis pain mechanisms, in collaboration with colleagues from Sheffield-Hallam University, U.K - see publications and CV.

Dr. Kean conducts ongoing research in the role of median nerve compression in relation to Osteoarthritis of the hands, and in relation to local hand and elbow pain - initial study published :- Kean W. F. Kean R. and Buchanan W. W. Osteoarthritis: symptoms, signs, and source of pain. Inflammopharmacology 2004; 12: 3-31. 2002 – 2011 - current.

He is currently investigating the musculoskeletal problems of the 5,300 year old Similuan Iceman with colleagues at the Museum of the Sud Tyrol, Bolzano Italy. 2004 – 2011 - current.

In collaboration with colleagues, Dr Kean is currently studying the biochemical toxicology of fabrics and related materials in the health care settings, of clinics, laboratories, surgical suites, etc – 2010 – 2011 -current.

Study on Osteoarthritis Pathogenesis: and Ibuprofen pharmcokinetics and dynamics in Hip and Knee Osteoarthritis – with Aleem Adatia, Medical Student (former Hamilton Health Sciences HBSc student), and Professor Kim Rainsford, Sheffield Hallam University, UK. 2009 – 2011 – current.

Selected Publications

Peer reviewed

  1. Gerecz-Simon EM, Kean WF. Methods for application of topical nonsteroidal anti-inflammatory drugs (TNSAIDs) in clinical trials. Inflammopharmacology, 1999: 7: 3:329.
  2. Gerecz-Simon EM, Kean WF. Efficacy and safety of topical nonsteroidal anti-inflammatory drugs (TSAIDs) in musculoskeletal disorders. Inflammopharmacology, 1999: 7: 3: 330.
  3. Kean, WF. Assessment of the clinical significance of cyclo-oxygenase inhibition in the therapy of rheumatic diseases. Inflammopharmacology. 1999. 17: 3: 316-317.
  4. Hungin AP, Kean WF. Nonsteroidal anti-inflammatory drugs: overused or underused in osteoarthritis. Am J Med, 2001; 110: 1A, 8S-11S.
  5. Buchanan WW, Kean, WF. Clinical judgement and evidence based medicine. Joint Bone Spine 2001; 68: 370-372.
  6. Buchanan WW, Kean WF. Rheumatoid arthritis: through long distance spectacles. Inflammopharmacology, 2001; 9: 3 - 22
  7. Buchanan WW, Kean WF. Osteoarthritis: I. Historical, Epidemiological and Risk Factors Considerations. Inflammopharmacology 2002;10:5 - 21
  8. Buchanan WW, Kean WF. Osteoarthritis: II. Pathology and Pathogenesis. Inflammopharmacology 2002; 10: 19-48.
  9. Buchanan WW, Kean WF. Osteoarthritis: III. Radiological and Clinical Definition. Inflammopharmacology 2002; 10: 53 -78
  10. Buchanan WW, Kean WF. Osteoarthritis: IV. Clinical Therapeutic Trials and Treatment. Inflammopharmacology 2002; 10: 79 - 155
  11. Smeija M, MacPherson D, Kean WF, Schmuck ML, Goldsmith C, Buchanan WW, Hart LE, Mahony JB. A randomised, blinded, placebo-controlled trial of doxycycline for chronic seronegative arthritis. Annals of the Rheumatic Diseases. 2001; 60: 1088-1094.
  12. Kean WF, Kean R, Buchanan WW. A critical assessment of oxaprozin clinical profile in rheumatic diseases. Inflammopharmacology 2002; 10: 214 - 284
  13. Kean WF, Buchanan WW, Kean R. Osteoarthritis: Symptoms and Signs. Inflammopharmacology 2003; in Pain in Osteoarthritis. eds K D Rainsford and M Powanda pp10 - 11.
  14. Buchanan W. W., Kean W. F., and Kean R. History and current status of osteoarthritis in the population. Inflammopharmacology 2003; 11: 301-316.
  15. Kean W. F. Kean R. and Buchanan W. W. Osteoarthritis: symptoms, signs, and source of pain. Inflammopharmacology 2004; 12: 3-31.
  16. Kean W. F. and Buchanan W. W. The use of NSAIDs in rheumatic disorders 2005: a global perspective. Inflammopharmacology 2005; 13: 343-370.
  17. Hawkey C, Talley NJ, Yeomans, ND, Jones R, Sung, JY, Langstrom G, Naesdal J, Scheiman J, Habbig J, Philippe F, Tondut J, Halland A, van Rensburg C, Karrasch J, Larnefelt H, Kean WF, Bjørneboe O, Halland A, Kjell-Arne Ung, Porro G, Patel A, Kleczkowski F, Vavincová P, Rovensky J, Labie F, Bolten, W, Lanas A, Bergmann J-F, Pál D. Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-asteroidal antiinflammatory drugs, including selective COX-2 inhibitors. Am J Gastroenterol 2005;100(5):1028-1036.
  18. Lippi G, Franchini M, Guidi GC, Kean WF.(2006) Non-steroidal anti-inflammatory drugs in athletes.
    Br J Sports Med. 40:661-2; discussion 662-3.
  19. Hawkey CJ, Talley NJ, Scheiman JM, Jones RH, Långström G, Næsdal J, Yeomans ND, Mielants H, Kean WF, et al. Maintenance treatment with esomeprazole following initial relief of non-steroidal anti-inflammatory drug-associated upper gastrointestinal symptoms: the NASA2 and SPACE2 studies.
    Arthritis Research & Therapy 2007, 9:R17.
  20. Kean WF, Rainsford KD, Kean IR. Management of chronic musculoskeletal pain in the elderly: opinions on oral medication use. Inflammopharmacology. 2008 Apr;16(2):53-75. Review.
  21. Kean WF, Kean IR. Clinical pharmacology of gold. Inflammopharmacology. 2008 Jun;16(3):112-25. Review. W.F. Kean
  22. Beattie KA, Bobba R, Bayoumi I, Chan D, Schabort I, Boulos P, Kean W, Obeid J, McCallum R, Ioannidis G, Papaioannou A, Cividino A. Validation of the GALS musculoskeletal screening exam for use in primary care: a pilot study. BMC Musculoskelet Disord. 2008 Aug 27;9:115.
  23. Rainsford KD, Kean WF, Ehrlich GE. Review of the pharmaceutical properties and clinical effects of the topical NSAID formulation, diclofenac epolamine. Curr Med Res Opin. 2008 Oct;24(10):2967-92. Epub 2008 Sep 23.
  24. Murtaugh K, Kean WF. The clinical assessment of transitional vertebrae and back pain. Inflammopharmacology. 2008 Dec;16(6):278-83.
  25. Kean W F, Sylvie Bouchard S, andGossen E R, Women with Pain due to Osteoarthritis: The Efficacyand Safetyof a Once-Daily Formulation of Tramadol, PainMedicine200910(6): 1001-1011.
  26. Zhang T, Adatia A, Zarin W, Moitri M, Vijenthira A, Chu R, Thabane L, Kean W. The efficacy of botulinum toxin type A in managing chronic musculoskeletal pain: a systematic review and meta analysis. Inflammopharmacology. 2011 Feb;19(1):21-34. Epub 2010 Nov 13.
  27. Beattie K, MacIntyre N, Pierbon J, Coombs J, Horobetz K, Petric A, Pimm M, Kean W, Larche M, Cividino A. The sensitivity, specificity and reliability of the GALS (gait, arms, legs and spine) examination when used by physiotherapists and physiotherapy students to detect rheumatoid arthritis.
    Physiotherapy 2011. doi:10.1016/j.physio.2010.11.008

Abstracts Presented at National and International Meetings 2008-2011

  1. Rainsford KD, Kean WF. Triad (G/I hepato-renal, CV) Composite Toxicities for Assessing Overall safety of NSAIDs. 50th Annual Meeting Australian Rheumatism Association , Adelaide 17-21 May 2008.
  2. Kean WF, Rainsford KD. Gold sodium thiomalate treatment for rheumatoid arthritis. Inflammopharmacology 2008; 16: 293. 9th International Conference on Inflammopharmacology, Side Effects of Anti- Inflammatory Drugs.Queen’s College Cambridge UK, Sept 8-10, 2008. Also presented as a lecture.
  3. Kean WF, Bouchard S, Gossen R. Women with Pain due to Osteoarthritis: Efficacy and Safety of a once-daily formulation of Tramadol. Inflammopharmacology 2008; 16: 310.
  4. 9th International Conference on Inflammopharmacology, Side Effects of Anti- Inflammatory Drugs. Queen’s College Cambridge UK, Sept 8-10, 2008. Also presented as a poster.

Editorials

  1. Buchanan WW, Kean, WF. Rheumatoid arthritis: beyond the lymphocyte. J Rheumatol. 2001; 28: 4, 691-693.
  2. Buchanan WW, Kean WF. Evidence-based medicine: the median is not the message. J Rheumatol. 2001; 28: 11, 2371-2372
  3. Kean W. Oxaprozin: kinetic and dynamic profile in the treatment of pain. Current Medical Research and Opinion 2004; 20: 1275-1277.

Historical

  1. Buchanan WW and Kean WF. Aspirin: The Rheumatologist’s Excalibur. Bull Royal Coll Phys Surg Glasgow. 2000: 29, 6-16
  2. Buchanan WW, Kean WF. The treatment of acute rheumatism by salicin, by T.J. Maclagan. The Lancet, 1876. J Rheumatol. 2002 Jun;29(6):1321-3.
  3. Buchanan WW and Kean WF. Dr William Bruce(1835 -1920): The Scottish Highland Spa at Strathpeffer and the first description of Polymyalgia Rheumatica. Journal of the Royal College of Physicians of Edinburgh 33: 2003
  4. Kean W. F. Balint G. and Buchanan W. W. History of the Development of the Microscope. Magyar Reumatologia 2004, 45: 73-84.
  5. Ballint GP, Kean WF, Buchanan WW. Sir William Osler (1849-1919): his opinion of modern therapeutics. Scott Med J. 2006 Mar;51(1):51-3.

Chapter in Book

See CV for additional Chapters in Books

Buchanan WW, Kean WF, Rainsford KD. Use of Salicylates in Rheumatic and Other Painful Conditions. In: Aspirin and Related Drugs.K.D Rainsford (ed) London 2004 , Ch. 12, pp 635-706.

Rainsford KD, Kean IRL, Kean WF. Gastrointestinal Complications of Anti-Rheumatic Drugs.
In: Digestive Involvement in Systemic Autoimmune Diseases, J. Font, M. Ramos-Casals and J. Rode´s, (Eds.) Handbook of Systemic Autoimmune Diseases. Volume 8, R. Asherton (Series Ed). Elsevier, Amsterdam, The Netherlands, 2008, Ch. 18, pp 243-275. W.F.Kean was the invited author.